Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Citius Oncology, Inc.NASDAQ: CTOR
Common Stock · Q2 FY2026 · quarter ended Mar 2026
Common stock rises 30.0% from a year ago
Common stock stood at $9.3K at the end of Q2 FY2026, up 30.0% from a year earlier and up 9.6% from the prior quarter. Over 3 fiscal years it compounded at +7.4% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +30.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 8.35K USD
- Year-over-year change
- +16.7%
- 3-year CAGR
- +7.4%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 8.35K | +16.7% |
| FY2024 | 2024-09-30 | 7.16K | +6.0% |
| FY2023 | 2023-09-30 | 6.75K | +0.0% |
| FY2022 | 2022-09-30 | 6.75K | — |
Common Stock vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 common stock of $9.3K is the 7th highest of the 10 companies compared; the peer median is $14K.
- Its year-over-year change of +30.0% is the 3rd highest of 10, against a peer median of +3.6%.
- Common stock amounts to 0.0% of total assets for CTOR, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $121K | +2.5% | +2.6% | 0.2% | |
| Mar 2026 | $116K | +0.9% | +5.8% | 0.0% | |
| Mar 2026 | $58K | +3.6% | +2.5% | 0.1% | |
| Mar 2026 | $19K | +46.2% | +37.0% | 0.0% | |
| Mar 2026 | $14K | +133.3% | -14.8% | 0.0% | |
| Mar 2026 | $10K | +11.1% | -56.9% | 0.0% | |
CTORCitius Oncology, Inc. | Mar 2026 | $9.3K | +30.0% | +7.4% | 0.0% |
| Mar 2026 | $3K | -99.9% | +44.2% | 0.0% | |
| Mar 2026 | $1K | +0.0% | -58.5% | 0.0% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $24 | +20.0% | +97.2% | 0.0% |
| Peer median (excluding CTOR) | $14K | +3.6% | +2.6% | 0.0% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.